ARTICLE | Company News
Germany again rebuffs Trobalt
April 15, 2014 11:30 PM UTC
Germany's Federal Joint Committee (G-BA) again concluded that epilepsy drug Trobalt retigabine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has "no additional benefit" vs. individualized antiepileptic therapy. According to G-BA, GSK did not submit complete, necessary data. The pharma, which does not market Trobalt in Germany, did not provide next steps in time for publication. Comments on the assessment are due May 6, with a final assessment from G-BA expected in early July. ...